SUVEN Life Sciences

Communication to investors

December 2010

Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW
Quarter 3 – Dec 2010

- Growth in revenue 10.71%
- Growth in PAT 55.60%
- Growth in EBIDTA -58.93%
- Growth in Pre-R&D EBIDTA -26.09%
- R&D cost on revenue 24.38%


FINANCIAL QUICK VIEW
Period ended Dec 2010

- Growth in revenue 12.65%
- Growth in PAT 27.27%
- Growth in EBIDTA -17.81%
- Growth in Pre-R&D EBIDTA - 6.52%
- R&D cost on revenue 22.31%


MAJOR PROFITABILITY RATIOS

	Q3 Dec 10	Q3 Dec 09	PE Dec 10	PE Dec 09
PAT to Income	3.50%	2.49%	6.56%	5.80%
EBIDTA to Income	2.49%	6.71%	8.19%	11.23%
Cash Flow to Income	7.80%	7.12%	10.44%	10.06%
Pre-R&D EBITDA to Income	26.87%	40.25%	30.50%	36.76%


INCOME COMPARISON




PROFIT COMPARISON




PRE-R&D EBIDTA




PRE-R&D CASHFLOW



R & D – EXPENDITURE



EBIDTA COMPARISON



Updates since last quarter

October 4-6, 2010

Suven participated at the Cambridge Healthtech Institute's **Third annual Conference, Accelerating Proof-of-Concept For Clinical Success** held at Philadelphia, PA, USA

Nov 13-19,2010

Suven presented several data presentations from their portfolio of investigational neuroscience new chemical entities (NCEs) at Society For Neuroscience (SFN) 2010 from 13th to 19th of Nov held at San Diego, USA.

Jan 11, 2011

Suven participated at **29th J.P. Morgan Healthcare Conference held in San Francisco, USA during 10th to 13th Jan 2011.**

Updates for the quarter


Dec 23, 2010

Suven granted four product patents, two **each from New Zealand (540842&572186) and Eurasia (012750 & 013875)** corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2022 and 2025 respectively.

Dec 30, 2010

Suven granted two product patents **241484 & 241819 from Indian Patent office** corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2027

SUVEN an end to end bio-pharmaceutical solutions company



Collaborative Research Partner (CRP) …

Seamless transition